CLINICAL TRIALS PROFILE FOR LAMISIL AT

All Clinical Trials for LAMISIL AT

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00002394 ↗	Safety and Effectiveness of Giving Lamisil to HIV-Positive Subjects With Thrush Who Have Not Responded to Fluconazole Treatment	Completed	Novartis	N/A	1969-12-31	The purpose of this study is to see if it is safe and effective to give Lamisil to HIV-positive patients with thrush (a fungal infection) that has not responded to fluconazole.
NCT00117767 ↗	Terbinafine Compared to Griseofulvin in Children With Tinea Capitis	Completed	Novartis Pharmaceuticals	Phase 3	2004-06-01	Tinea capitis is a dermatophyte infection of the scalp hair follicles, which occurs primarily in children. Hair loss, hair breakage, scaling, plus various degrees of erythema, pustules and pruritus are the primary clinical signs which can be associated with tinea capitis. The infection is caused by a relatively small group of dermatophytes in the genera Trichophyton and Microsporum. Terbinafine hydrochloride is a synthetic allylamine derivative antifungal agent. This study will evaluate the efficacy and safety of terbinafine in children with tinea capitis.
NCT00443820 ↗	Efficacy Safety, and Tolerability of Topical Terbinafine in Patients With Mild to Moderate Toenail Fungus of the Big Toenail	Completed	Novartis Pharmaceuticals	Phase 3	2006-12-01	This study is designed to assess the efficacy, safety and tolerability of a topical formulation of terbinafine solution applied daily in patients with toenail fungus. This trial will study patients with mild to moderate toenail fungus disease of the big toenail and their responses to two treatment durations, 24 or 48 weeks.
NCT00443898 ↗	Efficacy, Safety, and Tolerability of Topical Terbinafine in Patients With Mild to Moderate Toenail Fungus of the Big Toenail	Completed	Novartis Pharmaceuticals	Phase 3	2006-12-01	This study is designed to assess the efficacy, safety and tolerability of a topical formulation of terbinafine solution applied daily in patients with toenail fungus. This trial will study patients with mild to moderate toenail fungus disease of the big toenail and their responses to two treatment durations, 24 or 48 weeks.
NCT00459537 ↗	Efficacy, Safety and Tolerability of Topical 10% Terbinafine Hydrogen Chloride Versus 5% Amorolfine Nail Lacquer in Patients With Mild to Moderate Toenail Onychomycosis	Completed	Novartis	Phase 3	2007-03-01	This study will evaluate the efficacy, safety and tolerability of topical 10% terbinafine hydrogen chloride applied daily versus 5% amorolfine nail lacquer applied twice a week in patients with mild to moderate toenail onychomycosis, for a total treatment duration of 48 weeks.
NCT00602251 ↗	Bioequivalency Study of Terbinafine Tablets Under Fed Conditions	Completed	Roxane Laboratories	N/A	2004-03-01	The objective of this study was the bioequivalence of a Roxane Laboratories' terbinafine tablets, 250 mg, to Lamisil® Tablets, 250 mg (Novartis Pharmaceutical Corporation.) under fed conditions using a single-dose, randomized, 2-treatment, 2-period, 2-sequence crossover design.

Clinical Trial Conditions for LAMISIL AT

Condition Name

Condition Name for LAMISIL AT
Intervention	Trials
Onychomycosis	6
Healthy	5
HIV Infections	1
Itraconazole Adverse Reaction	1

Condition MeSH

Condition MeSH for LAMISIL AT
Intervention	Trials
Onychomycosis	7
Inflammatory Bowel Diseases	1
Tinea Capitis	1
Colitis	1

Clinical Trial Locations for LAMISIL AT

Trials by Country

Trials by Country for LAMISIL AT
Location	Trials
United States	48
Canada	3
Turkey	1
Iceland	1
Pakistan	1

Trials by US State

Trials by US State for LAMISIL AT
Location	Trials
Illinois	3
Pennsylvania	3
Oregon	3
Missouri	3
Virginia	3

Clinical Trial Progress for LAMISIL AT

Clinical Trial Phase

Clinical Trial Phase for LAMISIL AT
Clinical Trial Phase	Trials
Phase 3	5
Phase 2	2
Phase 1	8

Clinical Trial Status

Clinical Trial Status for LAMISIL AT
Clinical Trial Phase	Trials
Completed	17
Recruiting	2

Clinical Trial Sponsors for LAMISIL AT

Sponsor Name

Sponsor Name for LAMISIL AT
Sponsor	Trials
Novartis Pharmaceuticals	3
Teva Pharmaceuticals USA	2
Dr. Reddy's Laboratories Limited	2

Sponsor Type

Sponsor Type for LAMISIL AT
Sponsor	Trials
Industry	17
Other	5